All In MedTech

Device Trial Radar · NCT04434209

A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)

Limiting AKI Progression In Sepsis (LAPIS): A Phase 4, Multicenter, Randomized Controlled Trial of Biomarker-guided Delivery of Kidney-sparing Care Measures in Sepsis Subjects at Risk of Developing AKI

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

19

Actual

Start

Jan 19, 2021

Primary completion

Feb 14, 2022

Study completion Feb 14, 2022

Sponsor

Lead sponsor
BioMérieuxNot on our public-company list
Sponsor type
Industry
First posted
Jun 16, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Biomarkers that provide an early indicator of kidney stress could be useful in clinical practice to detect silent episodes of acute kidney injury (AKI) or for early identification of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators of AKI. The NephroCheck® test is a commercially available test that uses these biomarkers, and this study assesses the use of these in reducing negative clinical outcomes for patients with sepsis-associated AKI. The study will enroll subjects diagnosed with sepsis, including septic shock, who will be randomly assigned to either receive NephroCheck®-guided kidney-sparing and fast-tracking interventions; or to receive current Standard of Care assessment and treatment. NOTE: Participants are no longer being recruited to this study.

Conditions

  • Sepsis
  • Acute Kidney Injury
  • Septic Shock

Interventions

  • Subject management guided by NephroCheck® testDevice

    NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury

  • Standard of CareOther

    Standard of Care patient management

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of deaths, dialysis or progression of AKITime frame: Enrollment to 72 hours

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • LSU Health Sciences Center, 1541 Kings Highway

    Shreveport, Louisiana

  • Brigham and Womens Hospital, 75 Francis Street

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center, 1275 York Avenue

    New York, New York

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.